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OBJECTIVE— To assess whether TCF7L2 polymorphism has a role in the deterioration of
glycemic control.
RESEARCH DESIGN ANDMETHODS— Metabolic variables were evaluated at base-
line and after 6-year follow-up in 1,480 Caucasian subjects from a population-based cohort.
RESULTS— At baseline, T-allele carriers showed significantly lower BMI and homeostasis
model assessment for-cell function (HOMA-B) values and higher fasting glycemia and diabetes
prevalence. At follow-up, fasting glucose and HOMA-B index were increased and reduced,
respectively, in carriers of the T-allele. Incident impaired fasting glucose (IFG) and incident
diabetes were 5.7, 10.7, 16.9% and 1.6, 1.7, 3.0% in the CC, CT, and TT genotypes, respectively.
In a multiple logistic regression model, the association between incident IFG and the T-allele was
significant (odds ratio [OR] 2.08 [95% CI 1.35–3.20] and 3.56 [2.11–5.98] in CT and TT
genotypes, respectively).
CONCLUSIONS— The T-allele of TCF7L2 rs7903146 polymorphism was independently
associated with increasing fasting glucose values toward hyperglycemia in the follow-up.
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Among the variety of TCF7L2 poly-morphisms correlating with type 2diabetes, the single nucleotide
polymorphism (SNP) rs7903146 has
shown the strongest association with the
disease (1). We investigated the associa-
tion of the SNP rs7903146 with 1) type 2
diabetes or 2) impaired fasting glucose
(IFG) or 3) the metabolic syndrome (MS)
in an adult Italian population-based co-
hort both cross-sectionally and after
6-year follow-up.
RESEARCH DESIGN AND
METHODS— All 1,877 Caucasians
aged 45–64 years and representative of
the province of Asti (Italy) were invited to
participate in a metabolic survey in 2001–
2003; 1,658 (88.3%) agreed to partici-
pate by written informed consent. Both
participants and nonparticipants were
similar to the resident population of cor-
responding age with respect to sex com-
position, level of education, prevalence of
known diabetes, and living in a rural area
(2). Diabetes and MS were diagnosed ac-
cording to published recommendations
and criteria (3,4); the homeostasis model
assessment-insulin resistance (HOMA-
IR) index and the HOMA for -cell
(HOMA-B) function were calculated (5).
Genotyp ing for TCF7L2 SNP
rs7903146 utilized the real-time allele
discrimination method (Applied Biosys-
tems, Foster City, CA). All procedures
were in accordance with the Declaration
of Helsinki and approved by the local eth-
ics committee.
HOMA-IR, HOMA-B, insulin, and tri-
glyceride values were log-transformed
and used in all analyses. Multiple regres-
sion analyses (for continuous variables) or
multiple logistic regression analyses (for
dichotomic variables) were used to eval-
uate the associations between each vari-
able and the presence of the CT or TT
genotypes (introduced in the model as
dummy variables) after adjustments for
age, sex, familial diabetes, BMI, and waist
circumference. The capacity of the TT ge-
notype for predicting incident IFG and
diabetes was examined by calculating the
receiver operating characteristics (ROC)
curves and the area under the curve
(AUC).
RESULTS— From January to Novem-
ber 2008, patients were contacted for a
follow-up visit: 1,480/1,658 (89.3%)
were evaluated after excluding those who
died (n  61) and those whose blood
samples were not available for genotyping
(n  117). Mean follow-up was 6.1 
0.34 years. At baseline, 25.1% of patients
were on anti-hypertensive treatment and
4.7% were on hypoglycemic drugs.
Characteristics at baseline and fol-
low-up of subjects grouped by genotypes
are presented in Table 1. The rs7903146
genotypic distribution was in Hardy-
Weinberg equilibrium.
At baseline, carriers of the T-allele
showed significantly higher values of fast-
ing glucose and lower BMI and HOMA-B
index values in a regression model (Table
1). Prevalence of diabetes was signifi-
cantly higher in subjects carrying the mi-
nor T-allele in a multiple logistic
regression model, while no significant dif-
ferences were detected for prevalence of
IFG and MS.
At follow-up, fasting glucose and
HOMA-B values were increased and re-
duced, respectively, in T-allele carriers. In
these patients, prevalence of IFG, diabe-
tes, and MS were significantly higher in a
multiple logistic regression model in both
CT and TT genotypes (OR 1.78 [95% CI
1.06–2.99] and 3.10 [1.63–5.91] for di-
abetes; 1.81 [1.31–2.51] and [1.90 –
4.39] for IFG; 1.34 [1.02–1.75] and 1.79
[1.22–2.64] for MS in CT and TT geno-
types, respectively). The association be-
tween T-allele and MS was exclusively
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due to the higher prevalence of hypergly-
cemia in these subjects.
Incident diabetes was almost double
in homozygous for the T-allele, but the
association was not significant due to the
low case number. Incident IFG was two-
fold and threefold higher in the heterozy-
gous and homozygous T carriers,
respectively (OR 2.08 [95% CI 1.35–
3.20] and 3.56 [2.11–5.98] in CT and TT
genotypes, respectively). Adjustments for
smoking habits, lipid parameters, or
HOMA-B values did not significantly af-
fect the results. The AUCs of the ROC
curves for the TT genotype were 0.56 for
incident IFG and 0.54 for incident
diabetes.
CONCLUSIONS— The major find-
ings of the present study are: 1) a high
prevalence of the defective T-allele in an
Italian population-based cohort; 2) a sig-
nificant association between the T-allele
and hyperglycemia and -cell dysfunc-
tion at baseline and follow-up; 3) a two- to
threefold higher risk of incident IFG in
the T-allele carriers at follow-up; and 4)
an increased prevalence of MS in the
T-allele carriers.
The minor T-allele is strongly associ-
ated with reduced HOMA-B levels, sug-
gesting that the polymorphism could
affect the ability of the -cells to secrete
insulin. These data indicate that SNP
rs7903146 polymorphism may modulate
the degree of insulin secretion to offset the
prevailing level of insulin resistance with-
out being a cause of insulin resistance.
SNP rs7903146 acts like other TCF7L2
polymorphisms, such as rs12255372 (6).
The T-allele is significantly associated
with lower BMI, so we can confirm recent
studies that suggest that the variants do
not have a primary effect on adiposity (7).
These studies showed that individuals
with the highest risk genotype and the
lowest birth weight had the greatest risk
of type 2 diabetes (8).
It has been reported that TCF7L2 ex-
erts its influence through an impairment
of insulin secretion. This impairment was
reportedly due to a functional defect in
the glucagon-like peptide-1 (GLP-1) sig-
naling in -cells and not due to defective/
failing GLP-1 secretion (9). It is unlikely
that the pathway of incretins by itself can
play a central role in the pathophysiology
of type 2 diabetes. We reported that
TCF7L2 may impact -cell function both
directly through modulating -cell re-
sponse to glucose and indirectly by mod-
ulating incretin action or secretion (10).
The prevalence of MS in subjects car-
rying the TT genotype was about twofold
higher at follow-up when compared with
the prevalence at baseline. This increment
was almost exclusively due to the signifi-
cantly higher prevalence of hyperglyce-
mia in this subgroup. The AUC values are
similar to those reported in literature
dealing with one single SNP (11).
Our study confirms an effect of the
widely replicated TCF7L2 rs7903146
polymorphism on hyperglycemia in an
adult Italian population-based cohort
both in cross-sectional and longitudinal
evaluation. The independent association
of TCF7L2 polymorphism with increasing
fasting glucose values in the follow-up
may represent a marker for higher meta-
bolic risk, which is useful for developing
Table 1—Characteristics at baseline and follow-up by TCF7L2 rs7903146 genotypes
At baseline
CC CT P (95% CI) TT P (95% CI)
n 580 699 201
Frequency (%) 39.1 47.2 13.7
Male (%) 47.8 47.8 0.92* (0.98–1.02) 49.8 0.60* (0.80–1.46)
Diabetes in parents (%) 26.7 25.6 0.65* (0.73–1.21) 31.8 0.16* (0.90–1.82)
Age (years) 54.5  5.7 54.7  5.5 0.53† (0.42 to 0.82) 54.2  5.7 0.49† (0.58 to 1.22)
BMI (kg/m2) 27.0  4.9 26.6  4.6 0.12† (0.11 to 0.91) 26.0  4.0 0.01† (1.70 to 0.22)
Waist (cm) 92.3  13.2 91.7  12.7 0.39† (2.04 to 0.78) 89.9  12.5 0.02† (4.48 to 0.35)
SBP (mmHg) 133.9  16.4 134.1  15.6 0.57‡ (1.18 to 2.12) 133.6  15.9 0.52‡ (1.60 to 3.18)
DBP (mmHg) 83.7  9.4 83.4  9.3 0.83‡ (1.07 to 0.87) 82.5  9.0 0.83‡ (2.06 to 0.79)
LDL-C (mM/l) 3.3  1.0 3.3  0.9 0.95‡ (0.10 to 0.09) 3.4  0.9 0.47‡ (0.09 to 0.21)
HDL-C (mM/l) 1.6  0.4 1.5  0.3 0.13‡ (0.06 to 0.008) 1.6  0.4 0.78‡ (0.04 to 0.06)
Triglycerides (mM/l) 1.3 (0.9) 1.3 (0.8) 0.59‡ (0.06 to 0.04) 1.2 (0.7) 0.21‡ (0.11 to 0.03)
Glucose (mM/l) 5.7  1.4 5.9  1.5 0.02‡ (0.04–0.38) 6.2  2.7 0.001‡ (0.37–0.87)
Insulin (pM/l) 40.8 (21.6) 40.8 (19.8) 0.86‡ (0.03–0.04) 40.2 (16.2) 0.005 ‡ (0.12 to 0.02)
HOMA-B (U/ml/mM/l) 79.4 (44.6) 74.3 (44.6) 0.13 to 0.03 P  0.004‡ 73.2 (40.9) 0.29 to 0.13 p  0.001‡
HOMA-IR (mM/l  U/ml) 1.7 (1.0) 1.7 (1.0) 0.12‡ (0.01 to 0.08) 1.7 (0.8) 0.90‡ (0.07 to 0.06)
Diabetes (%) 3.8 6.6 0.01# (1.16–3.59) 8.0 0.006# (1.36–5.64)
Incident diabetes (%)
IFG (%) 12.9 15.3 0.18# (0.90 to 1.72) 15.9 0.16# (0.88–2.20)
Incident IFG (%)
MS (%) 24.1 24.3 0.49# (0.83–1.48) 18.9 0.70# (0.58–1.44)
Data are means SD or median (interquartile range) for not-normally distributed values. *P values calculated by a linear logistic regression analysis by evaluating
the association of gender or diabetes in parents with CT and TT genotypes; †P values calculated by a linear regression analysis by evaluating the association of age
or BMI or waist circumference with CT and TT genotypes; ‡P values calculated by a multiple regression analysis by evaluating the association of each of the variables
marked (one model for each variable) with CT and TT genotypes after adjusting for age, sex, BMI, waist circumference, and familial diabetes; #P values calculated
by a multiple logistic regression analysis by evaluating the association of each of the variables marked (one model for each variable) with CT and TT genotypes after
adjusting for age, sex, BMI, waist circumference, and familial diabetes; §data available in 1,031 subjects. DBP, diastolic blood pressure; HDL-C, HDL cholesterol;
LDL-C, LDL cholesterol; SBP, systolic blood pressure.
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more closely tailored lifestyle preventive
approaches as we have recently reported
(12).
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Table 1—Continued
At follow-up
CC CT P (95% CI) TT P (95% CI)
580 699 201
39.1 47.2 13.7
60.6  5.7 60.8  5.6 0.51† (0.41 to 0.83) 60.3  5.8 0.50† (0.59 to 1.22)
27.1  4.9 26.9  4.6 0.41 (0.72 to 0.29) 26.2  3.9 0.02† (1.65 to 0.17)
93.6  13.1 93.4  13.0 0.74† (1.63 to 1.15) 92.1  10.4 0.14† (3.56 to 0.52)
134.8  16.8 136.4  17.8 0.003‡ (0.18–3.66) 134.6  16.4 0.34‡ (1.30 to 3.78)
82.9  9.9 83.4  9.4 0.14‡ (0.25 to 1.73) 82.3  8.5 0.88‡ (1.56 to 1.34)
3.5  1.0 3.6  1.0 0.50‡ (0.07 to 0.15) 3.6  1.1 0.71‡ (0.13 to 0.19)
1.5  0.4 1.4  0.4 0.39‡ (0.06 to 0.02) 1.5  0.4 0.51‡ (0.08 to 0.04)
1.3 (0.9) 1.3 (0.8) 0.43‡ (0.03 to 0.07) 1.2 (0.8) 0.75‡ (0.08 to 0.06)
5.3  0.9 5.7  1.2 0.001‡ (0.30–0.54) 6.1  1.7 0.001‡ (0.60–0.96)
45.5 (38.8)§ 44.9 (34.3)§ 0.54‡ (0.11 to 0.06) 43.6 (31.1)§ 0.005‡ (0.30 to 0.06)
97.2 (85.4)§ 85.5 (74.6)§ 0.25 to 0.05 P  0.005‡ 75.4 (70.4)§ 0.50 to 0.20 P  0.001‡
1.7 (1.6)§ 1.8 (1.5)§ 0.12‡ (0.02 to 0.16) 1.9 (1.3)§ 0.20‡ (0.04 to 0.22)
4.5 7.0 0.03# (1.06–2.99) 10.5 0.001# (1.63–5.91)
1.6 1.7 0.75# (0.48–2.78) 3.0 0.15# (0.75–6.37)
11.2 18.0 0.001# (1.31–2.51) 25.4 0.001# (1.90–4.39)
5.7 10.7 0.001# (1.35–3.20) 16.9 0.001# (2.11–5.98)
27.9 31.5 0.04# (1.02–1.75) 33.3 0.003# (1.22–2.64)
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